CEBPZ and acute myeloid leukemia: Consistent with the previous studies, our study indicated that KIT mut/CBF-neg AML was a specific subgroup and showed a poor prognosis with a median EFS of 15.3 months and a median OS of 24.1 months, despite most patients categorized into favorable-risk and intermediate-risk subgroup based on ELN2022.